Clinical trial
Activated Protein C to Treat Acute Lung Injuries
NCT00112164 · University of California, San Francisco, Other · Terminated
Key facts
| NCT number | NCT00112164 |
|---|---|
| Title | Activated Protein C to Treat Acute Lung Injuries |
| Official title | Prospective, Randomized Phase II Clinical Trial of Activated Protein C (Xigris) Versus Placebo for the Treatment of Acute Lung Injury |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Heart, Lung, and Blood Institute (NHLBI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Respiratory Distress Syndrome, Adult |
| Intervention type | Drug |
| Interventions | Xigris |
| Enrollment | 90 |
| Start date | Jan 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | May 30, 2005 |
| Last update posted | Mar 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: